Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22192884
DOI
10.1016/j.drudis.2011.12.010
PII: S1359-6446(11)00437-5
Knihovny.cz E-resources
- MeSH
- Disulfiram therapeutic use MeSH
- Drug Industry economics MeSH
- Humans MeSH
- Neoplasms drug therapy MeSH
- Organizations, Nonprofit * MeSH
- Alcohol Deterrents therapeutic use MeSH
- Patents as Topic MeSH
- Delivery of Health Care MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Disulfiram MeSH
- Alcohol Deterrents MeSH
The effort to repurpose old drugs for new uses is not sufficient; even drugs that have been used clinically for decades must undergo expensive clinical trials. This process requires the pharmaceutical industry to fund the repatenting of old drugs. Because inexpensive drugs are necessary for people around the world, attempts should be made to develop nonprofit drugs through clinical trials of generic drugs that are funded by governments and charities. Evidence supports the use the old anti-alcoholic drug Antabuse as a new nonprofit drug for cancer.
References provided by Crossref.org
Multiple deadlocks in the development of nonprofit drugs
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Drug Repurposing for Terminal-Stage Cancer Patients
